LncRNA AC098613.1 promotes acute myeloid leukemia cell differentiation through CDC5L/ADAP1/NRD1 axis

Area of Science:

• Molecular Biology
• Oncology
• RNA Biology

Background:

• Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in leukemia.
• Differentiation therapy is a promising treatment strategy for acute myeloid leukemia (AML).
• Research on lncRNAs in AML differentiation therapy is limited.

Purpose of the Study:

• To investigate the role of AC098613.1 in the differentiation of acute myeloid leukemia (AML) cells.
• To elucidate the molecular mechanisms by which AC098613.1 influences AML cell behavior.
• To evaluate AC098613.1 as a potential therapeutic target for AML.

Main Methods:

• Analysis of AC098613.1 expression in differentiated THP-1 cells and AML patients.
• Overexpression of AC098613.1 in THP-1 and HL-60 cell lines.
• Investigation of molecular targets including CDC5L, ADAP1, NRD1, and CDK1.
• In vivo studies using animal models to assess tumor growth inhibition.

Main Results:

• AC098613.1 expression was significantly higher in differentiated THP-1 cells and lower in AML patients.
• AC098613.1 overexpression inhibited proliferation and induced differentiation in AML cell lines.
• AC098613.1 enhanced CDC5L stability, promoted ADAP1 transcription, and increased NRD1 expression.
• In vivo, AC098613.1 overexpression inhibited tumor growth by regulating CDC5L, ADAP1, NRD1, and CDK1.

Conclusions:

• AC098613.1 plays a crucial role in promoting AML cell differentiation.
• The mechanism involves the regulation of the CDC5L/ADAP1/NRD1 axis.
• AC098613.1 represents a novel and promising therapeutic target for AML differentiation therapy.